Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Through 2034?
The market for inhibitors of the calcitonin gene-related peptide (cgrp) has seen considerable expansion in the past few years. There is an expectation for this growth to continue, scaling from $2.87 billion in 2024 to an estimated $3.14 billion in 2025, projecting a compound annual growth rate (CAGR) of 9.6%. The notable growth in the historic period is linked to increased investment in research and development activities, rising approvals for new drugs, heightened demand for non-opioid pain relievers, and an emphasis on personalized medicine.
The market size for inhibitors of the calcitonin gene-related peptide (cgrp) is anticipated to undergo robust growth in the coming few years. It will expand to $4.58 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.9%. The expansion during the predicted period can be attributed to the rising prevalence of migraines, increasing use of preventive treatments for migraines, growing patient knowledge, and larger healthcare spending. Major trends within the forecasted period feature advances in medication formulation, utilization of digital health technology, advancements in precision medicine, and technological progress in biosimilars.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp
What Are the Core Growth Drivers Propelling the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Forward?
The escalating occurrences of migraines are anticipated to drive the expansion of the calcitonin gene-related peptide (CGRP) inhibitors market. Migraines, characterised by severe headaches often causing a throbbing sensation primarily on one side of the head, is accompanied by symptoms like nausea, vomiting, and sensitivity to light and sound. This rise in migraine cases is attributed to soaring stress levels, as persistent stress stimulates neural pathways. CGRP inhibitors are instrumental in managing migraines due to their targeted, preventative mechanism and compatibility with both short-term and long-term care plans. They lower the frequency and intensity of headaches by successfully blocking the CGRP receptors, thereby enhancing the patient’s well-being and everyday functionality. For example, a report published by the National Library of Medicine, a US health information institution, in January 2023 noted that the global percentage of people suffering from migraines ranges from 14% to 15%, adding up to 4.9% of the global disease burden. Consequently, the rising occurrences of migraines are fuelling the expansion of the calcitonin gene-related peptide (CGRP) inhibitors market.
What Segment Types Define the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Structure?
The calcitonin gene-related peptide (cgrp) inhibitors market covered in this report is segmented –
1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides
2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
3) By Route of Administration: Oral, Nasal, Intravenous
4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment
5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies
Subsegments:
1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality)
2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant
3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24182&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (CGRP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing theCalcitonin Gene-Related Peptide (CGRP) Inhibitors Industry Evolution?
Main players in the calcitonin gene-related peptide (CGRP) inhibitors market are honing in on creating cutting-edge products for gaining regulatory approvals, such as calcitonin gene-related peptide (CGRP) receptor antagonists, which are utilized to boost efficiency in migraine treatment. The companies are also working towards broadening therapeutic applications and incorporating simpler modes of administration, such as oral and intranasal routes. CGRP receptor antagonist is a medicine that curtails the activity of the calcitonin gene-related peptide (CGRP) receptor, subsequently obstructing pain signaling associated with migraines. To illustrate, in April 2023, U.S.-based biotechnology corporation, AbbVie Inc., gained approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant), a medication designed to manage chronic migraines in adults. QULIPTA is an orally administered CGRP receptor antagonist that operates by impeding CGRP receptors, which play a significant role in the pathophysiology of migraines, in turn, averting migraine episodes.
View the full report here:
What Is the Definition of the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
Calcitonin gene-related peptide (CGRP) inhibitors are a class of drugs that block the activity of the calcitonin gene-related peptide (CGRP) pathway, which is involved in transmitting pain and dilating blood vessels in the brain. These inhibitors help reduce the frequency and severity of migraines and are used as a treatment option in patients with chronic or episodic migraines.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24182
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
